Capivasertib联合阿比特龙治疗PTEN缺陷型新发转移性激素敏感性前列腺癌:CAPItello-281更新生存分析
CAPItello-281 III期研究更新分析显示,在PTEN缺陷型新发mHSPC患者中,Capivasertib联合阿比特龙对比安慰剂联合阿比特龙在42%OS成熟度时OS获益(HR 0.82,95%CI 0.68-0.99,P=0.044;中位OS 57.4 vs 46.5个月),rPFS更新结果与主要分析一致,安全性特征不变。
要点
- rPFS更新结果与主要分析一致,HR 0.83。
- 安全性特征与主要分析保持一致。
核心结论
- 在PTEN缺陷型新发mHSPC患者中,Capivasertib联合阿比特龙对比安慰剂联合阿比特龙显示OS获益,支持其作为该预后不良人群的靶向治疗选择。
研究设计与样本
- III期CAPItello-281研究(NCT04493853),随机1:1分配,1012例PTEN缺陷型新发mHSPC患者接受Capivasertib联合阿比特龙(n=507)或安慰剂联合阿比特龙(n=505),均联合泼尼松/泼尼松龙和雄激素剥夺治疗。
主要发现
- 42%OS成熟度时,Capivasertib联合阿比特龙对比安慰剂联合阿比特龙OS HR 0.82(95%CI 0.68-0.99,P=0.044),中位OS 57.4 vs 46.5个月。
- 更新rPFS HR 0.83(95%CI 0.70-0.99,名义P=0.033),中位rPFS 35.5 vs 26.0个月。
- 安全性特征与主要分析一致。
关键数值与推荐
- PTEN缺陷定义为≥90%存活恶性细胞免疫组化无特异性胞质染色。
- 主要分析rPFS HR 0.81(95%CI 0.66-0.98,P=0.034)。
- 本次分析为42%OS成熟度时的描述性分析,数据截止2026年3月9日,中位随访39个月。
临床怎么用
- 对于PTEN缺陷型新发mHSPC患者,可考虑在阿比特龙联合ADT基础上加用Capivasertib以改善生存获益。
局限性
- 本次更新分析为描述性、非方案预设分析。
- OS数据成熟度为42%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with phosphatase and tensin homolog (PTEN)-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC) have poor prognosis and reduced benefit from current standard of care. The phase III CAPItello-281 study (NCT04493853) showed a statistically significant benefit in radiographic progression-free survival (rPFS) with capivasertib plus abiraterone versus placebo plus abiraterone (combined with prednisone/prednisolone and androgen deprivation therapy): hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.66-0.98; P=0.034. The HR for interim overall survival (OS; 26% maturity) was 0.90, 95% CI 0.71-1.15. Here, we report ad hoc, descriptive analyses at 42% OS data maturity. PATIENTS AND METHODS: Patients with de novo mHSPC and PTEN-deficient tumors (defined as ≥90% of viable malignant cells with no specific cytoplasmic staining by immunohistochemistry) received capivasertib plus abiraterone or matched placebo (randomized 1:1) plus abiraterone. Analyses performed at this ad hoc data cut-off, including the alpha-controlled key secondary endpoint of OS as well as the primary endpoint of investigator-assessed rPFS, were descriptive and not prespecified in the protocol. RESULTS: 1012 patients received capivasertib plus abiraterone (n=507) or placebo plus abiraterone (n=505). At this ad hoc analysis at 42% OS maturity (data cut-off: March 9, 2026), with 17 months' additional follow-up (median follow-up 39 months in both arms), HR for OS favored capivasertib plus abiraterone versus placebo plus abiraterone (HR 0.82, 95% CI 0.68-0.99, P=0.044) and OS medians were reached: 57.4 versus 46.5 months. Updated rPFS (HR 0.83, 95% CI 0.70-0.99, nominal P=0.033; median 35.5 versus 26.0 months) was consistent with the primary analysis. The safety profile remained consistent with the primary findings. CONCLUSIONS: With longer follow-up, findings from this updated descriptive analysis support the clinically meaningful OS benefit of adding capivasertib to abiraterone in the treatment of patients with PTEN-deficient mHSPC. Capivasertib plus abiraterone represents a first-in-class targeted treatment approach for this poor prognosis population with high unmet need.
引用
- Fizazi K, Clarke NW, De Santis M, et al. Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281. Ann Oncol. 2026. PMID: 42918424. doi:10.1016/j.annonc.2026.10.097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。